GastroPlus在预测特定人群PK的应用文章 （2011—2020年10月）
导 读
凡默谷技术部精取了2011-2020年10月GastroPlus在预测特定人群PK的应用文章35篇。
其中编号1-8的文章是2019年8月-2020年10月新增的文章。
Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Successful Extrapolation of Paracetamol Exposure from Adults to Infants After Oral Administration of a Pediatric Aqueous Suspension Is Highly Dependent on the Study Dosing Conditions.
Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling.
Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
Ontogeny of Hepatic Sulfotransferases and Prediction of Age-Dependent Fractional Contribution of Sulfation in Acetaminophen Metabolism.
Physiologically Based Pharmacokinetic Modeling to Evaluate Formulation Factors Influencing Bioequivalence of Metoprolol Extended-Release Products.
Prediction of ticagrelor and its active metabolite in liver cirrhosis populations using a physiologically based pharmacokinetic model involving pharmacodynamics.
Physiologically Based Pharmacokinetic/ Pharmacodynamic Model for Caffeine Disposition in Pregnancy.
Pediatric Physiologically Based Pharmacokinetic Model Development: Current Status and Challenges.
12. 通过PBPK和模型中的虚拟人群考察生理学对曲马多Tramadol儿科PK预测的影响
PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.
T’jollyn H, Vermeulen A, Van Bocxlaer J. AAPS J. January 2019, 21:8. IF=3.737
13. 通过整合的PBPK模型，对比达沙替尼Dasatinib不同的儿科用药制剂的生物等效性，并阐明相应的吸收机制
Bioequivalence comparison of pediatric Dasatinib formulations and elucidation of absorption mechanisms through integrated PBPK modeling.
Vaidhyanathan S, Wang X, Crison JR, Varia S, Gao J, Saxena A, Good D. J Pharm Sci. January 2019 Volume 108, Issue 1, Pages 741–749. IF=3.616
14. 使用酮康唑作为模型药物的计算机工具在临床实践中的应用
Application of in silico Tools in Clinical Practice using Ketoconazole as a Model Drug.
Silva DA, Duque MD, Davies NM, Löbenberg R, Ferraz HG. J Pharm Pharm Sci.2018;21(1s):242s-253s. IF=0.69
15. 在评估儿科口服药品中生物药剂学的考虑因素-PEARRL综述
Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review.
Guimarães M, Statelova M, Holm R, Reppas C, Symilllides M, Vertzoni M, Fotaki N.J Pharm Pharmacol. 2018 Jul 3. IF=2.571
16. 用于考察普通病人、重症监护病房和肝功能不全患者的全身生理药代动力学PBPK模型，以卡泊芬净Caspofungin为案例
Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.
Yang QT, Zhai YJ, Chen L, Zhang T, Yan Y, Meng T, Liu LC, Chen LM, Wang X, Dong YL. Acta Pharmacol Sin. 2018 May 31. IF=1.736
17. mTORC1 / 2抑制剂sapanisertib（TAK-228）口服研磨制剂的I期研究：在晚期实体瘤患者中的耐受性和食物效应
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
Moore KN, Bauer TM, Falchook GS, Chowdhury S, Patel C, Neuwirth R, Enke A, Zohren F, Patel MR. ESMO Open. 2018 Feb 1;3(2): e000291.
18. 在长期服用厄洛替尼erlotinib的期间，监测在胰腺癌患者中的行为，并与生理药代动力学PBPK模型的预测结果进行比较
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.
Gruber A, Czejka M, Buchner P, Kitzmueller M, Kirchbaumer Baroian N, Dittrich C, Sahmanovic Hrgovcic A. Cancer Chemother Pharmacol. 2018 Apr;81(4):763-771.IF=2.967
19. 考察口服卡马西平在儿童人群中的吸收
Investigating Oral Absorption of Carbamazepine in Pediatric Populations.
Kohlmann P, Stillhart C, Kuentz M, Parrott N. AAPS J. 2017 Nov;19(6):1864-1877.IF=3.737
20. 用于促进弱碱性药物制剂处方开发的生物相关性溶出模型，并克服因胃酸分泌过少或胃酸缺乏导致的低生物利用度
Biorelevant Dissolution Models for a Weak Base To Facilitate Formulation Development and Overcome Reduced Bioavailability Caused by Hypochlordyria or Achlorhydria.
Kou D, Dwaraknath S, Fischer Y, Nguyen D, Kim M, Yiu H, Patel P, Ng T, Mao C, Durk M, Chinn L, Winter H, Wigman L, Yehl P. Mol Pharm. 2017 Oct 2;14(10):3577-3587. IF=4.321
21. 开发具有非典型分布行为的药物的PBPK模型及资质：以地昔帕明为例
Development and qualification of physiologically based pharmacokinetic models for drugs with atypical distribution behavior: A desipramine case study.
Samant T S, Lukacova V, Schmidt S. CPT: Pharmacometrics & Systems Pharmacology, 2017. CiteScore=5.2
22. Danirixin盐型药物在降低患者群体中的PK变异度因素的识别和表征
Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations.
Bloomer J C, Ambery C, Miller B E, et al. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117: 224-231. IF=4.604
23. 采用计算机模拟了解肾功能损伤对二甲双胍口服吸收影响的机制
Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations.
Almukainzi M, Gabr R, Abdelhamid G, et al. Journal of Pharmaceutical Investigation, 2017, 47(2): 151-161.
24. 采用机制性吸收模型研究哌甲酯口服缓释制剂在成人体内的药动学曲线
Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults.
Yang X, Duan J, Fisher.J. PloS one, 2016, 11(10): e0164641. IF=2.74
25. 用于预测更昔洛韦及其前药缬更昔洛韦在成人和儿童体内行为的生理药代动力学PBPK模型
A Physiologically Based Pharmacokinetic Model for Ganciclovir and Its Prodrug Valganciclovir in Adults and Children.
Lukacova V, Goelzer P, Reddy M, et al. The AAPS journal, 2016, 18(6): 1453-1463.IF=3.737
26. 通过特定疾病的模型模拟美洛昔康和布洛芬在不同疾病状态与健康状况下的PK
Disease specific modeling: simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions.
Almukainzi M, Jamali F, Aghazadeh-Habashi A, Löbenberg R. (2016) Eur. J. Pharm. Biopharm. Jan. 2. IF=4.604
27. 用于儿科肿瘤药物开发的生理药代动力学PBPK模型
Physiologically-Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.
Rioux N, Waters NJ. (2016) Drug Metab Dispos. Mar 2. IF=3.231
28. 使用生理药代动力学PBPK模型深入了解生理因素对口服药物在儿童人群中吸收的影响
Using Physiologically Based Pharmacokinetic (PBPK) Modelling to Gain Insights into the Effect of Physiological Factors on Oral Absorption in Paediatric Populations.
Villiger A, Stillhart C, Parrott N, Kuentz M. (2016) AAPS J. Apr 8. IF=3.737
29. 开发用于预测吲哚美辛在孕妇体内处置的PBPK/PD模型
Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.
Alqahtani S, Kaddoumi A. (2015). PLoS One. Oct 2;10(10). IF=2.74
30. 氧化物酶体增殖物激活受体PPAR的神经保护作用，用于治疗帕金森病认知障碍中的PPAR激动剂：行为，生物化学和PBPK预测曲线
Uppalapati D, Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS. (2014)PPAR Research; Article ID 753587. IF=2.953
31. 模拟胃肠道旁路手术后患者服用二甲双胍后的吸收
Modelling the Absorption of Metformin with Patients Post Gastric Bypass Surgery.
Almukainzi M, Lukacova V, Löbenberg R. (2014) J Diabetes Metab. 5:353.IF=3.099
32. PPAR-β/ d激动剂具有神经保护作用，可减少啮齿动物帕金森病模型的认知障碍
A PPAR-ß/d Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson's Disease.
Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS. (2014). Curr Neurovasc Res. Mar 18. IF=1.649
33. 采用简化的PBPK建模方法，预测主要经肾排泄和CYP3A代谢的四种化合物在妊娠期间的PK
A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy.
Xia B, Heimbach T, Gollen R, Nanavati C, He H. (2013) AAPS J. Jul 9. IF=3.737
34. 开发奥司他韦基于生理学的模型，并用于模拟在新生儿和婴儿的PK
Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.
Parrott N, Davies B, Hoffmann G, Koerner A, Lave T, Prinssen E, Theogaraj E, Singer T. (2011). Clin Pharmacokinet. 50(9):613-23. IF=4.604
35. 生理药代动力学PBPK模型：方法论，应用和局限性，重点关注其在儿科药物开发中的作用
Physiologically Based Pharmacokinetic Modeling: Methodology, Applications, and Limitations with a Focus on Its Role in Pediatric Drug Development.